Aprea Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. (Nasdaq: APRE) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Doylestown, Pennsylvania, the company is focused on precision oncology and the development of targeted cancer therapies built around DNA damage response (DDR) biology and synthetic lethality. Its strategy is to identify vulnerabilities in cancer cells and translate them into small-molecule therapies that may deliver antitumor activity while aiming to reduce damage to healthy tissue. ([ir.aprea.com](https://ir.aprea.com/investor-relations/?utm_source=openai)) Aprea’s roots trace back to Aprea Therapeutics AB, which was originally incorporated in 2002 and began principal operations in 2006. The U.S. company Aprea Therapeutics, Inc. was incorporated in June 2016, reflecting the evolution of the business from its earlier Scandinavian origins into a Nasdaq-listed oncology platform. The company’s development history and current structure suggest a long-term scientific focus rather than a commercial-stage model, with value creation dependent on clinical execution, biomarker selection, and data readouts. ([ir.aprea.com](https://ir.aprea.com/static-files/ca97aed5-79ff-4762-8b27-6960f910c102?utm_source=openai)) The company’s pipeline is currently anchored by two lead clinical programs. APR-1051 is an oral, selective WEE1 kinase inhibitor being evaluated in the ACESOT-1051 study in solid tumors. ATRN-119 is an oral ATR inhibitor under clinical development for solid-tumor indications as well. Both programs sit within Aprea’s broader DDR-focused platform, and both are designed to exploit cancer-specific vulnerabilities. For investors, this means the company is not a diversified oncology player; rather, it is a highly specialized, program-driven developer whose outlook depends on the quality of emerging clinical data. ([aprea.com](https://aprea.com/aprea-therapeutics-pipeline/?utm_source=openai)) In competitive terms, Aprea operates in a crowded precision-oncology landscape dominated by large pharmaceutical companies and better-capitalized biotech peers. As a result, the company’s differentiation comes from scientific selectivity, early clinical signals, and intellectual property strength rather than market share or commercial reach. Aprea has emphasized its global patent portfolio, which supports its WEE1 and ATR programs and is important for protecting future optionality. The company remains pre-commercial and therefore has no marketed product revenue base at this stage. ([ir.aprea.com](https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-strengthens-global-patent-portfolio-dna?utm_source=openai)) Recent developments have been material. In 2026, Aprea reported a confirmed partial response in the ongoing ACESOT-1051 trial for APR-1051, reinforcing early clinical proof-of-concept. The company also announced an oversubscribed private placement expected to generate about $30 million in gross proceeds, and it reported first-quarter 2026 financial results in May 2026. Earlier, Aprea received a Nasdaq non-compliance notice in January 2026 related to minimum bid price requirements, a key listing risk that investors should monitor closely. Overall, the story remains one of clinical-stage optionality, capital needs, and execution risk, with upcoming data releases likely to be the principal catalysts. ([nasdaq.com](https://www.nasdaq.com/press-release/aprea-therapeutics-highlights-positive-emerging-clinical-activity-wee1-inhibitor-apr?utm_source=openai))